Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women
- PMID: 22010008
- PMCID: PMC3221522
- DOI: 10.1200/JCO.2010.33.6446
Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women
Abstract
Purpose: Triple-negative breast cancers (TNBCs) are tumors with low or no expression of estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2. These tumors have a poor prognosis, remain a clinical challenge, and are more common among women with BRCA1 mutations. We tested whether there are distinguishing features of TNBC after BRCA1 mutation status has been taken into account.
Patients and methods: We sequenced BRCA1 and BRCA2 genes in a population-based sample of 1,469 patients with incident breast cancer age 20 to 49 years from Los Angeles County (California). Information on tumor receptor status was available for 1,167 women. Clinical, pathologic, and hormone-related lifestyle characteristics were compared across patient subgroups defined by BRCA1 mutation status and triple-negative receptor status.
Results: Forty-eight percent of BRCA1 mutation carriers had TNBC compared with only 12% of noncarriers. Within BRCA1 mutation carriers, as well as within noncarriers, triple-negative receptor status was associated with younger age at diagnosis and higher tumor grade. Among women without a BRCA1 mutation, we observed that women with TNBC had higher premenopausal body mass index and earlier age at first full-term pregnancy than those with non-TNBC. Age at menarche and other reproductive factors were not associated with triple-negative status regardless of BRCA1 mutation status. Within BRCA1 mutation carriers, Ashkenazi Jewish women were about five times more likely to have TNBC than non-Ashkenazi Jewish women.
Conclusion: Our results suggest that among BRCA1 mutation carriers, as among noncarriers, there are unique characteristics associated with the triple-negative subtype. The findings in Ashkenazi Jewish BRCA1 mutation carriers should be confirmed.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Comment in
-
Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations.J Clin Oncol. 2012 Dec 10;30(35):4447-8. doi: 10.1200/JCO.2012.44.5635. Epub 2012 Oct 22. J Clin Oncol. 2012. PMID: 23091104 No abstract available.
Similar articles
-
Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.Breast Cancer Res Treat. 2011 Aug;129(1):185-90. doi: 10.1007/s10549-011-1433-2. Epub 2011 Mar 11. Breast Cancer Res Treat. 2011. PMID: 21394499 Free PMC article.
-
Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.Breast Cancer Res Treat. 2012 Apr;132(2):421-8. doi: 10.1007/s10549-011-1596-x. Epub 2011 May 26. Breast Cancer Res Treat. 2012. PMID: 21614564
-
Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93. Am J Surg Pathol. 2009. PMID: 19390427
-
"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.Semin Oncol. 2011 Apr;38(2):254-62. doi: 10.1053/j.seminoncol.2011.01.007. Semin Oncol. 2011. PMID: 21421115 Review.
-
Triple-negative breast cancer: disease entity or title of convenience?Nat Rev Clin Oncol. 2010 Dec;7(12):683-92. doi: 10.1038/nrclinonc.2010.154. Epub 2010 Sep 28. Nat Rev Clin Oncol. 2010. PMID: 20877296 Review.
Cited by
-
Circulating cell-free miRNAs as biomarker for triple-negative breast cancer.Br J Cancer. 2015 May 26;112(11):1751-9. doi: 10.1038/bjc.2015.143. Epub 2015 Apr 23. Br J Cancer. 2015. PMID: 25906045 Free PMC article.
-
Minireview: Obesity and breast cancer: a tale of inflammation and dysregulated metabolism.Mol Endocrinol. 2013 May;27(5):715-25. doi: 10.1210/me.2013-1011. Epub 2013 Mar 21. Mol Endocrinol. 2013. PMID: 23518927 Free PMC article. Review.
-
The BRCAness Landscape of Cancer.Cells. 2022 Dec 1;11(23):3877. doi: 10.3390/cells11233877. Cells. 2022. PMID: 36497135 Free PMC article.
-
Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).J Pathol Clin Res. 2019 Jul;5(3):189-198. doi: 10.1002/cjp2.133. Epub 2019 May 23. J Pathol Clin Res. 2019. PMID: 31041842 Free PMC article.
-
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status.Breast Cancer Res Treat. 2014 Aug;147(1):185-91. doi: 10.1007/s10549-014-3056-x. Epub 2014 Jul 22. Breast Cancer Res Treat. 2014. PMID: 25048467 Free PMC article.
References
-
- Hudis CA. Trastuzumab: Mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39–51. - PubMed
-
- Riggs BL, Hartmann LC. Selective estrogen-receptor modulators: Mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618–629. - PubMed
-
- Reis-Filho JS, Tutt AN. Triple negative tumours: A critical review. Histopathology. 2008;52:108–118. - PubMed
-
- Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer. 2007;109:1721–1728. - PubMed
-
- Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–2334. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous